[CAS NO. 290304-24-4] Daun02
PRODUCTS SPECIFICATIONS [290304-24-4]
DESCRIPTION [290304-24-4]
Overview
| MDL | MFCD22124459 |
|---|---|
| Molecular Weight | 884.79 |
| Molecular Formula | C41H44N2O20 |
| SMILES | O[C@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)OC2=CC=C(C=C2[N+]([O-])=O)COC(N[C@@H]3[C@@H]([C@@H](O[C@H](C3)O[C@H]4C[C@](C(C)=O)(CC5=C(C(C(C6=C7C(OC)=CC=C6)=O)=C(C(O)=C54)C7=O)O)O)C)O)=O)CO |
3 Publications Citing Use of MCE
Summary
Daun02 is a prodrug of the topoisomerase inhibitor Daunorubicin.
IC50 & Target
|
Topoisomerase |
Daunorubicins/Doxorubicins |
In Vitro
Daun02 is a prodrug, which is converted by β-galactosidase to Daunorubicin, which has been shown to reduce calcium ion (Ca 2+ )-dependent action potentials in neuroblastoma cells [1] . Daunorubicin is a topoisomerase inhibitor [2] . Daun02 is a good substrate for β-galactosidase (β-gal). The concentration of Daun02 producing 50% (EC 50 ) decrease in cell viability is 0.5 μM, 1.5 μM, and 3.5 μM for T47-D, Panc02, and MCF-7, respectively [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Daun02 is a good substrate for β-gal with K m and V max values of 0.37 mM and 8.6 μmol/min/mg protein. At a concentration of 10 -5 M, Daun02 is 79% bound to plasma protein compares to 94% for Daunomycin [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 113.02 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.1302 mL | 5.6511 mL | 11.3021 mL |
| 5 mM | 0.2260 mL | 1.1302 mL | 2.2604 mL |
| 10 mM | 0.1130 mL | 0.5651 mL | 1.1302 mL |
-
1.
References
- [1] Koya E, et al. Targeted disruption of cocaine-activated nucleus accumbens neurons prevents context-specific sensitization. Nat Neurosci. 2009 Aug;12(8):1069-73.
- [2] Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7.
- [3] Farquhar D, et al. Suicide gene therapy using E. coli beta-galactosidase.Cancer Chemother Pharmacol. Cancer Chemother Pharmacol. 2002 Jul;50(1):65-70.
